

1 Durable reprogramming of neutralising antibody 2 responses following breakthrough Omicron infection

3 Wen Shi Lee^{1†}, Hyon-Xhi Tan^{1†}, Arnold Reynaldi², Robyn Esterbauer¹, Marios
4 Koutsakos¹, Julie Nguyen¹, Thakshila Amarasena¹, Helen E Kent¹, Anupriya
5 Aggarwal², Stuart G Turville², George Taiaroa³, Paul Kinsella³, Kwee Chin Liew³,
6 Thomas Tran³, Deborah A Williamson^{3,4}, Deborah Cromer², Miles P Davenport²,
7 Stephen J Kent^{1,5}, Jennifer A Juno¹, David S Khoury², Adam K Wheatley^{1*}

8
9 ¹Department of Microbiology and Immunology, University of Melbourne, Peter
10 Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

11 ²Kirby Institute, University of New South Wales, Kensington, New South Wales,
12 Australia

13 ³Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital
14 at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

15 ⁴Department of Infectious Diseases, The University of Melbourne at the Peter
16 Doherty Institute for Infection and Immunity, Victoria, 3000, Australia

17 ⁵Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred
18 Hospital and Central Clinical School, Monash University, Melbourne, Victoria,
19 Australia

20
21 †Contributed equally

22 *Corresponding author: a.wheatley@unimelb.edu.au

23 24 **Abstract**

25 SARS-CoV-2 breakthrough infection of vaccinated individuals is increasingly
26 common with the circulation of highly immune evasive and transmissible Omicron
27 variants. Here, we report the dynamics and durability of recalled spike-specific
28 humoral immunity following BA.1 or BA.2 breakthrough infection, with longitudinal
29 sampling up to 8 months post-infection. Both BA.1 and BA.2 infection robustly
30 boosted neutralisation activity against the infecting strain while expanding breadth
31 against other Omicron strains. Cross-reactive memory B cells against both ancestral
32 and Omicron spike were predominantly expanded by infection, with limited

33 recruitment of *de novo* Omicron-specific B cells or antibodies. Modelling of
34 neutralisation titres predicts that protection from symptomatic reinfection against
35 antigenically similar strains will be remarkably durable, but is undermined by novel
36 emerging strains with further neutralisation escape.

37

38 ***One sentence summary***

39 Omicron breakthrough infection elicits durable neutralising activity by recalling cross-
40 reactive vaccine-elicited memory B cells.

41 Introduction

42 SARS-CoV-2 continues to cause significant morbidity and mortality. While currently
43 licensed vaccines based on the ancestral strain of SARS-CoV-2 (Wuhan-Hu-1) are
44 effective at preventing severe COVID-19, they have reduced effectiveness at
45 preventing infection with novel variants that escape vaccine-elicited neutralising
46 antibodies. The Omicron variant is highly antigenically distinct and rapidly
47 outcompeted the Delta variant to become the dominant global strain in early 2022.
48 Various sub-lineages of Omicron (BA.1, BA.2, BA.4, BA.5 and others), each with
49 different degrees of antibody evasion, have since emerged in successive waves (1,
50 2). The high transmissibility and immune evasion of Omicron, in tandem with waning
51 of vaccine-elicited immunity, have resulted in increasing frequencies of
52 “breakthrough” infections of vaccinated individuals. At a population level, immunity
53 against SARS-CoV-2 is thus becoming increasingly complex, with variable dosing
54 and types of vaccines, infection with distinct variants, or a combination of both
55 (hybrid immunity).

56

57 Recent studies of antibody and memory B cell responses following breakthrough
58 infection with Delta or Omicron BA.1 have established rapid anamnestic recall of
59 spike-specific antibody responses, reactivation of spike-specific memory B cells and
60 differentiation of antibody-secreting cells (3-5). Breakthrough Omicron infection in
61 individuals with 2 prior vaccine doses has also been associated with increases in the
62 breadth of serum neutralising antibody activity compared to those receiving a third
63 dose of vaccine (3, 6). Increased neutralising breadth could be derived from *de novo*
64 antibody responses against neo-epitopes within Omicron spike, or alternatively the
65 selective re-expansion of cross-reactive memory B cells established during

66 vaccination. Here we intensively examined the early kinetics of recalled immunity
67 following Omicron BA.1 or BA.2 breakthrough infections, as well as profiled the
68 durable changes in serological neutralisation breadth following recovery. We find that
69 breakthrough infections, despite mild disease course, were highly efficient at both
70 recalling spike-specific memory responses established by prior immunisation, as well
71 as generating novel responses to the viral nucleocapsid. While BA.1 or BA.2
72 neutralising titres were low or undetectable at early timepoints following infection,
73 these responses expanded robustly and demonstrated breadth against the more
74 escaped BA.4 variant. Longitudinal follow up revealed remarkably stable
75 maintenance of Omicron-specific neutralising activity, which we then modelled to
76 estimate the protective window against reinfection with the same or novel variants
77 with further immune escape. Understanding the impact of periodic infection with
78 increasingly distinct SARS-CoV-2 variants upon the durability and breadth of
79 antibody and memory B cell immunity will be critical to informing optimal design and
80 deployment of COVID-19 vaccines to maximise population-level protection against
81 future variants.

82

83 Results

84 ***BA.1 or BA.2 breakthrough infection drives high viral loads and is*** 85 ***immunogenic despite mild disease course***

86 Twenty-six vaccinated individuals (3 with two prior vaccines, 21 with three prior
87 vaccines and 2 previously infected with ancestral virus and subsequently vaccinated)
88 were recruited following Omicron breakthrough infection that occurred at a median of
89 95 days (IQR 78-124) after receiving their last COVID vaccine dose (Table S1). All
90 individuals reported a mild but symptomatic disease course. Omicron BA.1 infection
91 was confirmed using whole genome sequencing for 8 individuals, and BA.2
92 confirmed for 15 individuals, with the remaining presumptively designated BA.1 (2
93 individuals) or BA.2 (1 individual) infections based on the prevalent variants
94 circulating at the time. Serial blood samples and nasal swabs were obtained up to
95 247 days of follow up, with intensive sampling during the acute infection phase
96 (Figure 1A).

97

98 SARS-CoV-2 viral load in nasal swabs was measured via qPCR of the nucleocapsid
99 (N) gene (Figure 1B). Omicron BA.1 and BA.2 breakthrough infection showed similar
100 viral kinetics, with most individuals displaying peak viral load upon recruitment at
101 around 1-3 days post-symptom onset. Median peak Ct values were consistent with
102 previous reports demonstrating robust viral replication during Omicron breakthrough
103 infection despite prior immunisation (7, 8). 19 of 21 individuals in our cohort had no
104 prior documented COVID-19 infection and were immunised with COVID-19 vaccines
105 encoding only the spike antigen (BNT162b2, ChAdOx1 nCoV-19, mRNA-1273, NVX-
106 CoV2373) (Table S1). Supporting this, serological responses against SARS-CoV-2 N
107 were at low or undetectable levels at the earliest timepoints sampled (Figure 1C).

108 However, a clear and consistent expansion of N-specific IgG was observed in
109 plasma samples from ~7 days post-symptom onset, with similar trajectories for both
110 BA.1 and BA.2 breakthrough infection (Table S2). Overall, individuals with Omicron
111 breakthrough infection in our cohort exhibited marked viral replication in the upper
112 respiratory tract and seroconverted to N.

113

114 ***Durable boosting of neutralising antibody responses following BA.1 or BA.2*** 115 ***breakthrough infection***

116 At the earliest sampled timepoint following infection (<5 days post-symptom onset),
117 the majority of subjects had robust serological neutralisation activity against
118 ancestral SARS-CoV-2 virus (VIC01), but low or undetectable neutralisation titres
119 against BA.1 or BA.2 (Figure 2A). Neutralising titres against the ancestral strain were
120 rapidly recalled by infection, starting from day 3-4 onwards and concomitant with
121 rises in neutralisation activity against the matched infecting strain. One BA.1-infected
122 individual (CP69) had a transient rise in BA.1 neutralisation activity from days 9-21,
123 before waning to undetectable levels at day 44 post-symptom onset. However, in all
124 other subjects, recovery from infection was associated with robust boosting of BA.1
125 or BA.2 plasma neutralisation activity.

126

127 We applied a piecewise linear regression model to parameterise the kinetics of
128 antibody recall, including estimates of the initial period of delay, the rate of increase,
129 and time to maximal titres (Table S3). The initial delay phase before detectable
130 increases in neutralising activity against the homologous infecting strain was similar
131 between BA.1 or BA.2 infected subjects, at 3.1 and 3.6 days respectively, with a
132 doubling time of 2.1 and 2.8 days thereafter. Robust expansion of BA.1 and BA.2

133 neutralising activity against the infecting homologous strains was observed in both
134 BA.1 and BA.2 infected cohorts (31- and 34.7-fold respectively), contrasting with the
135 more modest rise of neutralising activity against VIC01 (5.4- and 15.6-fold
136 respectively).

137

138 We next examined the breadth of neutralising antibody responses following
139 breakthrough infection with a panel of Omicron variants including the more immune
140 evasive BA.4 variant. At around 1-month post-symptom onset (median 34 days, IQR
141 28.5-36.5), individuals with BA.1 breakthrough infection had median neutralisation
142 titres of 1188 against VIC01, 190 against BA.1, 316 against BA.2 and 176 against
143 BA.4 while individuals with BA.2 breakthrough infection had median titres of 5038
144 against VIC01, 616 against BA.1, 1468 against BA.2 and 936 against BA.4 (Figure
145 2B). The degree of escape relative to ancestral virus was consistent between the two
146 cohorts, at ~6-fold for BA.1, ~4-fold for BA.2 and ~6-fold for BA.4. Neutralising titres
147 were consistently higher in subjects with BA.2 breakthrough infection, however this is
148 likely reflective of higher baseline titres in these individuals rather than any
149 differential immunogenicity between BA.1 and BA.2.

150

151 The longevity of neutralising antibody responses following breakthrough infection
152 was examined in a subset of BA.1-infected (n=7, days 167-247) and BA.2-infected
153 subjects (n=8, days 80-155) (Table S1). After BA.1 infection, BA.1 neutralising titres
154 were stably maintained and readily detectable 5-8 months post-infection, with a half-
155 life of 334 days (Figure 2C, Table S4). An exception was a single subject (CP69)
156 who did not have detectable titres after day 44. Neutralisation against ancestral
157 VIC01 decayed at a half-life of 183 days and remained high (>1:1000) for all

158 individuals at the late timepoint. Durable BA.2-specific neutralising responses were
159 similarly observed in BA.2-infected subjects, with a half-life of 1050 days. Notably, 4
160 out of 8 BA.2-infected individuals exhibited an increase in neutralising activity
161 between early and late timepoints, indicating that peak titres may have occurred
162 more than 1-month post-symptom onset (Figure 2C, Table S4). Neutralisation
163 against ancestral VIC01 virus was comparably durable and maintained over the 3–4-
164 month period, with a half-life of 1216 days.

165

166 ***Omicron BA.1 and BA.2 breakthrough infection recalls antibodies that are***
167 ***predominantly cross-reactive against ancestral SARS-CoV-2 spike***

168 Robust and broad neutralising responses against Omicron strains following
169 breakthrough infection could derive from recalled immunological memory or
170 comprise *de novo* BA.1 or BA.2-specific antibodies. We pre-incubated plasma
171 samples with Wuhan-Hu-1 spike or a BSA control to sequester antibodies that bind
172 to ancestral spike, and probed for residual binding activity against BA.1 or BA.2
173 spike by IgG ELISA. In plasma samples taken during the first week post-symptom
174 onset, pre-incubation with ancestral spike eliminated any residual binding to the BA.1
175 and BA.2 spike, with no evidence for omicron-specific reactivity (Figure 2D).
176 However, after recovery (~1-month post-symptom onset), low titres of antibodies
177 specific for BA.1 alone were detected in 3 of 8 individuals. In contrast, no BA.2-
178 infected subjects had antibodies specific for BA.2 alone. This demonstrates that
179 antibody responses to BA.1 and BA.2 breakthrough infection is dominated by cross-
180 reactive specificities that also bind to ancestral spike.

181

182 ***Omicron BA.1 and BA.2 breakthrough infection primarily recalls memory B***
183 ***cells cross-reactive with ancestral SARS-CoV-2 spike***

184 In individuals with prior SARS-CoV-2 immunity established by ancestral spike
185 vaccines, Omicron breakthrough infection could potentially broaden the memory B
186 cell repertoire by eliciting B cells against neo-epitopes within Omicron spike. We
187 therefore examined the recall of cross-reactive spike-specific memory B cells
188 established primarily through prior vaccination or the elicitation of *de novo* Omicron-
189 specific memory B cells. Spike-specific memory B cells within PBMC samples were
190 stained using a combination of fluorescent spike probes (ancestral Wuhan Hu-1
191 spike in combination with either BA.1 or BA.2 spike; gating in Figure S1). We
192 observed substantial expansion of class-switched memory B cells (CD19+ IgD-) that
193 were cross-reactive to SARS-CoV-2 ancestral spike and BA.1/BA.2 spike (Figure
194 3A). Frequencies of cross-reactive memory B cells peaked around 1-month post-
195 symptom onset, before subsequently waning over 100 days of follow up (Figure 3B).
196 We did not observe notable expansion of monospecific memory B cells against
197 either BA.1 or BA.2 Spike (Figure 3A). BA.1 and BA.2 monospecific memory B cells
198 were on average 7 and 16-fold lower than their cross-reactive counterparts around 1-
199 month post-symptom onset, with frequencies remaining unchanged throughout the
200 longitudinal sampling period (Figure 3B).

201

202 A large proportion of cross-reactive memory B cells exhibited an activated phenotype
203 (CD21- CD27+) in PBMC samples taken ~day 10 post-symptom onset (median 58%),
204 indicating efficient antigen recall during Omicron breakthrough infection, which later
205 waned over the course of recovery (median 14% at ~day 160) (Figure 3C). We
206 observed a distinct lack of activation of BA.1 or BA.2 monospecific memory B cells,

207 suggesting these cells likely represent background binding or B cells with low affinity
208 for spike (Figure 3C). Cross-reactive memory B cells were predominantly IgG+ at all
209 timepoints, with minor subpopulations of IgA+ or IgM+ isotypes (Figure 3D). In
210 contrast, 45-60% of BA.1/BA.2 monospecific memory B cells were IgG+, which
211 remained relatively unchanged after breakthrough infection, suggesting limited
212 exposure to antigen in vivo. Overall, our data suggests that the cross-reactive
213 memory B cells predominates the recall response, with Omicron-specific populations
214 remaining unexpanded, following Omicron breakthrough infection.

215

216 ***Estimated protection against reinfection following breakthrough infection is***
217 ***robust but moderated by immune escape***

218 The immunity gained at a population level via breakthrough infection remains unclear.
219 Using the previously developed model for predicting protection from symptomatic
220 infection based on neutralisation titres (9), we estimated the durability of protection
221 following Omicron breakthrough infection (Figure 4A, 4B). Since decay rates of
222 neutralising antibodies against the infecting strains were not significantly different
223 across BA.1 or BA.2 breakthrough infection, nor across different variants (ancestral
224 vs Omicron) (Table S4), we pooled neutralisation data for all subjects across all
225 variants and fitted a linear mixed effects model to estimate an average decay rate of
226 880 days. Using the geometric mean peak neutralisation titres from BA.1 and BA.2
227 breakthrough infection and the global decay rate, we predict that 70% protective
228 efficacy against the homologous infecting strain would last approximately 4.5 years
229 for BA.1 breakthrough and 7 years for BA.2 breakthrough. Similarly durable
230 protective efficacy was estimated for the ancestral variant, lasting more than 8.5 and
231 10 years above 70% for BA.1 and BA.2 breakthrough respectively. Forecasting

232 protection to a variant to which participants had not been exposed (e.g., BA.4),
233 protective efficacy was predicted to be maintained above 70% for 705 and 1607
234 days for BA.1 and BA.2 breakthrough respectively.

235

236 Given the continued emergence of Omicron sub-lineages with additional immune
237 escape mutations, we next modelled the impact of immune evasion on the stability of
238 protection against symptomatic reinfection in a population that gained hybrid
239 immunity by Omicron BA.1 or BA.2 breakthrough infection. Notably, even at
240 timepoints where plasma neutralisation activity is maximal (~1 month post-symptom
241 onset), a novel variant with 3- or 10-fold reduction in neutralisation would reduce the
242 protective efficacy from 90.1% to 74.1% or 46.8% respectively for BA.1 hybrid
243 immune individuals, and from 95.3% to 85.5% or 63.4% respectively for BA.2 (Figure
244 4C, 4D). These fold change estimates are highly relevant, as comparable reductions
245 in neutralisation activity have already been observed with recent Omicron
246 sublineages BQ.1.1 and XBB (10). Overall, our modelling suggests that recovery
247 from an Omicron breakthrough infection confers remarkably durable protection
248 against closely related viral strains, but this protection can be rapidly subverted by
249 the emergence of novel variants with increasing escape from neutralising antibodies.

250

251 Discussion

252 The marked immune evasiveness and transmissibility of Omicron strains are driving
253 increasing numbers of vaccine breakthrough infections worldwide, although the
254 durability of immunity elicited by such infections remain unclear. Using intensive
255 longitudinal sampling, we find both BA.1 or BA.2 breakthrough infection drive
256 expansion of neutralising responses against the infecting strains from low or
257 undetectable levels to high titres that were stably maintained from around 1 month
258 post-symptom onset. Importantly, we show that only cross-reactive memory B cells
259 were expanded by breakthrough infection, and the resulting antibody response was
260 dominated by antibodies cross-reactive with ancestral spike, indicating that limited
261 *de novo* responses were generated against neo-epitopes within BA.1 or BA.2 spike.

262

263 In line with recent studies (3, 11), our results are suggestive of immune imprinting,
264 with no evident increase in BA.1 or BA.2 monospecific B cells even up to 4-7 months
265 post-infection. Interestingly, Kaku et al. reported that BA.1 breakthrough infection
266 drove affinity maturation of cross-reactive B cells and antibodies towards Omicron
267 BA.1 over time (11), although our data suggests mechanistically this occurs through
268 selective re-expansion of B cell memory. While the isolation of receptor binding
269 domain (RBD)-specific monoclonal antibodies (mAbs) specific for the BA.1 RBD that
270 do not cross-react with ancestral RBD has been reported, these comprised only a
271 small fraction (median 4%) of the response to RBD (11), confirming that neo-
272 epitopes are poorly recognised during breakthrough infection. Immune imprinting is
273 not constrained to breakthrough infections, as monovalent Omicron BA.1 or bivalent
274 Beta/Delta mRNA vaccines also predominantly boost pre-existing cross-reactive
275 responses (12).

276

277 While superficially attractive, “overcoming” immune imprinting to generate responses
278 against neo-epitopes may not actually be favourable for protection. Primary infection
279 with Omicron elicits very limited neutralising breadth against historical non-Omicron
280 variants (13). Similarly, Omicron-specific mAbs isolated from BA.1, BA.2 or BA.5
281 breakthrough individuals that do not bind ancestral RBD exhibit very narrow breadth
282 of recognition, with little to no neutralisation activity against more recent Omicron
283 variants including BQ.1.1 and XBB (10).

284

285 It remains unclear if there is something unique about “hybrid immunity” (vaccination
286 then infection) in terms of durable reprogramming of the antibody response.
287 Epidemiological studies have indicated that hybrid immunity confers stronger and
288 more durable protection against infection compared to vaccine- or infection-elicited
289 immunity alone (14-17). In line with other reports (6, 18), our data suggest that BA.1
290 and BA.2 breakthrough infection confers neutralisation breadth that extend to the
291 more immune evasive BA.4 variant. Studies of a third dose of an ancestral spike
292 vaccine have similarly demonstrated expansion of Omicron-specific B cells and
293 enhancement of neutralisation breadth (19, 20), although not to the same extent as
294 breakthrough infection with BA.1 (6). It remains to be seen whether the bivalent
295 ancestral + BA.1 or ancestral + BA.5 mRNA vaccines can elicit equivalent levels of
296 neutralisation breadth to Omicron breakthrough infection. Intriguingly, Muik et al.
297 showed that neutralisation of BA.2 and BA.4/5 mediated by BA.2 breakthrough sera
298 is highly dependent on antibodies against the N-terminal domain (NTD) of spike,
299 while BA.1 breakthrough sera-mediated neutralisation is almost exclusively
300 dependent on RBD antibodies (21). The different antibody targets elicited by BA.1 vs

301 BA.2 breakthrough infection may have implications for immunity towards future
302 Omicron variants, depending on which region of spike (RBD and/or NTD) gains
303 further escape mutations (10, 22).

304

305 Both waning immunity and immune escape of new variants contribute to
306 susceptibility of SARS-CoV-2 reinfection, though the relative contribution of these
307 two factors is unknown. Here, we modelled the level of immune boosting and rate of
308 antibody waning after breakthrough infection with BA.1 and BA.2 variants. Our
309 analysis suggests robust and prolonged immunity to the homologous strain (70%
310 protective efficacy for 4.5 and 7 years following BA.1 or BA.2 breakthrough infection).
311 However, this protection is rapidly undermined by the emergence of more escaped
312 variants. For example, a variant with a 3-fold reduction in neutralising antibody titre
313 would reduce protective efficacy by the same amount expected after 3.8 years of
314 waning immunity. A novel variant with a 10-fold reduction in neutralising antibody
315 titre would reduce protective efficacy to 46.8% and 63.4% immediately following
316 BA.1 or BA.2 breakthrough infection. This suggests that waning immunity likely plays
317 a relatively small role in the ongoing susceptibility of SARS-CoV-2, especially with
318 the emergence of BQ.1.1 (BA.5-derived) and XBB (BA.2-derived) variants that have
319 displayed 9-37 fold drops in neutralisation relative to the homologous infecting
320 strains in BA.1/BA.2 breakthrough cohorts (10, 23, 24).

321

322 Repeated, sequential waves of Omicron outbreaks have driven significant
323 breakthrough infections and conferred “hybrid” immunity to much of the global
324 population. Our data suggests that continuing spread of SARS-CoV-2 in this immune

325 landscape will be less a function of waning immunity and in large part depend on the
326 viral acquisition of further neutralisation escape mutations.

327 **Materials and methods**

328 ***Human subjects and ethics***

329 A cohort of previously vaccinated participants with breakthrough COVID-19 (either
330 PCR or rapid antigen test positive) were recruited through contacts with the
331 investigators and invited to provide serial blood and nasal swab samples following
332 symptom onset (Table S1), some of whom were previously described (5). Infecting
333 variant was confirmed via whole genome sequencing of nasal swabs. For three
334 participants where early nasal swabs were not available, the infecting variant was
335 assigned based on predominant circulating strain at the time of infection. For all
336 participants, whole blood was collected with sodium heparin anticoagulant. Plasma
337 was collected and stored at -80°C, and PBMCs were isolated via Ficoll-Paque
338 separation, cryopreserved in 10% DMSO/FCS and stored in liquid nitrogen. Study
339 protocols were approved by the University of Melbourne Human Research Ethics
340 Committee (2021-21198-15398-3, 2056689), and all associated procedures were
341 carried out in accordance with approved guidelines. All participants provided written
342 informed consent in accordance with the Declaration of Helsinki.

343

344 ***Analysis of viral RNA load by qPCR***

345 For viral RNA extraction, 200 µL of nasal swab sample was extracted with the
346 QIAamp 96 Virus QIAcube HT kit (Qiagen, Germany) on the QIAcube HT System
347 (Qiagen) according to manufacturer's instructions. Purified nucleic acid was then
348 immediately converted to cDNA by reverse transcription with random hexamers
349 using the SensiFAST cDNA Synthesis Kit (Bioline Reagents, UK) according to
350 manufacturer's instructions. cDNA was used immediately in the rRT-PCR or stored
351 at -20°C. Three microlitres of cDNA was added to a commercial real-time PCR

352 master mix (PrecisionFast qPCR Master Mix; Primer Design, UK) in a 20 μ L reaction
353 mix containing primers and probe with a final concentration of 0.8 μ M and 0.1 μ M for
354 each primer and the probe, respectively. Samples were tested for the presence of
355 SARS-CoV-2 nucleocapsid (N) genes using previously described primers and
356 probes (25, 26). Thermal cycling and rRT-PCR analyses for all assays were
357 performed on the ABI 7500 FAST real-time PCR system (Applied Biosystems, USA)
358 with the following thermal cycling profile: 95°C for 2 min, followed by 45 PCR cycles
359 of 95°C for 5 s and 60°C for 30 s for N gene.

360

361 ***ELISA (N IgG and blocking ELISA)***

362 Antibody binding to SARS-CoV-2 N protein was tested by ELISA. 96-well Maxisorp
363 plates (Thermo Fisher) were coated overnight at 4°C with 2 μ g/mL recombinant
364 N. After blocking with 1% FCS in PBS, duplicate wells of serially diluted plasma were
365 added and incubated for two hours at room temperature. Bound antibody was
366 detected using 1:20,000 dilution of HRP-conjugated anti-human IgG (Sigma) and
367 plates developed using TMB substrate (Sigma), stopped using sulphuric acid and
368 read at 450nm. Endpoint titres were calculated using Graphpad Prism as the
369 reciprocal serum dilution giving signal 2 \times background using a fitted curve (4
370 parameter log regression).

371

372 For blocking ELISA, plates were coated overnight with recombinant BA.1 or BA.2
373 spike proteins (Hexapro ectodomain (27)). Plasma samples were pre-incubated in
374 20 μ L PBS with 1 μ g of ancestral spike protein, or BSA control for 1 hour prior to serial
375 dilution in PBS+1%FCS containing 5 μ g/ml ancestral spike protein or BSA. Diluted

376 plasma was added to the coated plate and incubated at room temperature for 30min,
377 before washing and developing as described above.

378

379 ***SARS-CoV-2 virus propagation and titration***

380 Ancestral SARS-CoV-2 (VIC01) isolate was grown in Vero cells in serum-free DMEM
381 with 1µg/ml TPCK trypsin while Omicron BA.1, BA.2 and BA.4 strains were grown in
382 Calu3 cells in DMEM with 2% FCS. Cell culture supernatants containing infectious
383 virus were harvested on Day 3 for VIC01 and Day 4 for Omicron strains, clarified via
384 centrifugation, filtered through a 0.45µm cellulose acetate filter and stored at -80°C.
385 Infectivity of virus stocks was then determined by titration on HAT-24 cells (a clone of
386 transduced HEK293T cells stably expressing human ACE2 and TMPRSS2 (28)). In
387 a 96-well flat bottom plate, virus stocks were serially diluted five-fold (1:5-1:78,125)
388 in DMEM with 5% FCS, added with 30,000 freshly trypsinised HAT-24 cells per well
389 and incubated at 37°C. After 46 hours, 10µl of alamarBlue™ Cell Viability Reagent
390 (ThermoFisher) was added into each well and incubated at 37°C for 1 hour. The
391 reaction was then stopped with 1% SDS and read on a FLUOstar Omega plate
392 reader (excitation wavelength 560nm, emission wavelength 590nm). The relative
393 fluorescent units (RFU) measured were used to calculate %viability ('sample' ÷ 'no
394 virus control' × 100), which was then plotted as a sigmoidal dose response curve on
395 Graphpad Prism to obtain the virus dilution that induces 50% cell death (50%
396 infectious dose; ID₅₀). Each virus was titrated in quintuplicate in three independent
397 experiments to obtain mean ID₅₀ values.

398

399 ***SARS-CoV-2 microneutralisation assay with viability dye readout***

400 In 96-well flat bottom plates, heat-inactivated plasma samples were diluted 2.5-fold
401 (1:20-1:12,207) in duplicate and incubated with SARS-CoV-2 virus at a final
402 concentration of $2 \times ID_{50}$ at 37°C for 1 hour. Next, 30,000 freshly trypsinised HAT-24
403 cells in DMEM with 5% FCS were added and incubated at 37°C. ‘Cells only’ and
404 ‘Virus+Cells’ controls were included to represent 0% and 100% infectivity
405 respectively. After 46 hours, 10µl of alamarBlue™ Cell Viability Reagent
406 (ThermoFisher) was added into each well and incubated at 37°C for 1 hour. The
407 reaction was then stopped with 1% SDS and read on a FLUOstar Omega plate
408 reader (excitation wavelength 560nm, emission wavelength 590nm). The relative
409 fluorescent units (RFU) measured were used to calculate %neutralisation with the
410 following formula: $(\text{‘Sample’} - \text{‘Virus+Cells’}) \div (\text{‘Cells only’} - \text{‘Virus+Cells’}) \times 100$. IC_{50}
411 values were determined using four-parameter non-linear regression in GraphPad
412 Prism with curve fits constrained to have a minimum of 0% and maximum of 100%
413 neutralisation.

414

415 ***Flow cytometric detection of SARS-CoV-2 spike-reactive B cells***

416 Biotinylated recombinant SARS-CoV-2 Spike of ancestral Wuhan Hu-1 and Omicron
417 (BA.1 or BA.2) strains were conjugated to streptavidin-APC or -PE fluorophores,
418 respectively. PBMCs were thawed and stained with Aqua viability dye (Thermo
419 Fisher Scientific) and then surface stained with Spike probes, CD19 ECD (J3-119)
420 (Beckman Coulter), IgA VioBlue (IS11-8E10) IgM BUV395 (G20-127), IgD PE-Cy7
421 (IA6-2), IgG BV786 (G18-145), CD21 BUV737 (B-ly4), CD27 BV605 (O323),
422 streptavidin BV510 (BD Biosciences), CD14 BV510 (M5E2), CD3 BV510 (OKT3),
423 CD8a BV510 (RPA-T8), CD16 BV510 (3G8), and CD10 BV510 (HI10a) (BioLegend).
424 Cells were washed twice with PBS containing 1% FCS and fixed with 1%

425 formaldehyde (Polysciences) and acquired on a BD LSR Fortessa using BD FACS
426 Diva.

427

428 ***Modelling the kinetics of antibody recall and decay***

429 We used a piecewise model to estimate the activation time and growth rate of
430 various immune responses (neutralization and N IgG responses) following
431 breakthrough infections. The model of the immune response y for subject i at time y_i
432 can be written as:

$$y_i(t) = \begin{cases} (B + b_i); & t \geq T_1 + \tau_{1i} \\ (B + b_i)e^{(G+g_i)(t-(T_1+\tau_{1i}))}; & T_1 + \tau_{1i} \leq t < T_2 + \tau_{2i} \\ (B + b_i)e^{(G+g_i)((T_2+\tau_{2i})-(T_1+\tau_{1i}))} \times e^{-(D+d_i)(t-(T_2+\tau_{2i}))}; & t \geq T_2 + \tau_{2i}. \end{cases}$$

433 The model has 5 parameters; B, G, T_1, D , and T_2 . For a period before T_1 , we assumed
434 a constant baseline value B for the immune response. After the activation time T_1 ,
435 the immune response will grow at a rate of G until T_2 . From T_2 , the immune response
436 will decay at a rate of D . For each subject i , the parameters were taken from a
437 normal distribution, with each parameter having its own mean (fixed effect). A
438 diagonal random effect structure was used, where we assumed there was no
439 correlation within the random effects. The model was fitted to the log-transformed
440 data values, with a constant error model distributed around zero with a standard
441 deviation σ . To account for the values less than the limit of detection, a censored
442 mixed effect regression was used to fit the model. A categorical covariate was used
443 to quantify the difference in parameters between different groups (i.e. BA.1 vs BA.2
444 group), and significance was determined based on the value of this binary covariate
445 using a Wald test. Model fitting was performed using MonolixR2019b.

446

447 The decay rate of neutralisation was estimated by fitting a linear mixed effect model
448 for each response variable as a function of days post-symptom onset, infection wave
449 (i.e. BA.1 and BA.2), and response type (WT, matched, and BA.4). Likelihood ratio
450 test was used to determine if the decay rate is different with respect to infection wave
451 and response type. We fitted the model to log-transformed data of various response
452 variables (assuming exponential decay), and we censored the data from below if it
453 was less than the threshold for detection. The model was fitted by using *lme4* library
454 in *R* (v4.2.1), using the maximum likelihood algorithm to fit for the fixed effects.

455

456 ***Predicting vaccine efficacy to different variants after breakthrough infection***

457 We used the previously published model for predicting vaccine efficacy for a given
458 plasma neutralisation titre (9). This model relates the neutralisation titre normalised
459 to the geometric mean neutralisation titre against ancestral virus, of a convalescent
460 cohort (individuals infected with the ancestral virus), with vaccine efficacy. Thus, we
461 first estimated the geometric mean peak neutralisation titre for BA.1 and BA.2
462 breakthrough infections against three variants (the ancestral virus, the matched
463 breakthrough variant and BA.4), and normalised these to a previously reported
464 cohort (n=8) of convalescent individuals (29) using the same neutralisation assay
465 (Geometric mean neutralisation titre of this cohort 507.6). Pooling the data on the
466 decay of neutralisation across all individuals and variants we estimated the kinetics
467 of neutralisation against each of these variants up to 3650 days after the peak.
468 These predicted kinetics of neutralisation titres were then used in the model by
469 Khoury et al. to predict vaccine efficacy at each neutralisation titre using the formula:

$$VE(n(t)) = \int_{-\infty}^{\infty} N(x : \log_{10}(n(t)), \sigma) \frac{1}{1 + e^{-k \cdot (x - x_{50})}} dx$$

470

471 where $N(x; \mu, \alpha)$ is the probability density function of a normal distribution with
472 mean μ and standard deviation α , σ is the standard deviation of \log_{10} neutralisation
473 titres of the vaccinated population, $n(t)$ is the geometric mean neutralisation titre at
474 time t days after the peak neutralisation titre (normalised to the geometric mean of
475 the convalescent cohort), and x_{50} is the \log_{10} neutralisation titre associated with 50%
476 protection. The parameters σ , k and x_{50} were estimated in Khoury et al. along with
477 standard errors of the parameter estimates (9). Confidence intervals of the
478 predictions were estimated by parametric bootstrapping as described previously (30).
479 In brief, 10,000 random samples of the estimated peak neutralisation titre, decay rate,
480 and model parameters σ , k and x_{50} were randomly drawn from normal distributions
481 around the mean estimates of each parameter using the standard error of each
482 estimate or covariance matrix where appropriate, the VE was estimated using the
483 above equation for each set of sampled parameters and the 2.5th and 97.5th
484 percentiles of the bootstrapped estimates at each neutralisation titre were calculated
485 as the lower and upper 95% confidence bounds, respectively (indicated by shaded
486 region in figure 4).
487

488 References

- 489 1. H. Tegally, M. Moir, J. Everatt, M. Giovanetti, C. Scheepers, E. Wilkinson, K.
490 Subramoney, Z. Makatini, S. Moyo, D. G. Amoako, C. Baxter, C. L. Althaus, U.
491 J. Anyaneji, D. Kekana, R. Viana, J. Giandhari, R. J. Lessells, T. Maponga, D.
492 Maruapula, W. Choga, M. Matshaba, M. B. Mbulawa, N. Msomi, N.-S.
493 consortium, Y. Naidoo, S. Pillay, T. J. Sanko, J. E. San, L. Scott, L. Singh, N.
494 A. Magini, P. Smith-Lawrence, W. Stevens, G. Dor, D. Tshiabuila, N. Wolter,
495 W. Preiser, F. K. Treurnicht, M. Venter, G. Chiloane, C. McIntyre, A. O'Toole,
496 C. Ruis, T. P. Peacock, C. Roemer, S. L. Kosakovsky Pond, C. Williamson, O.
497 G. Pybus, J. N. Bhiman, A. Glass, D. P. Martin, B. Jackson, A. Rambaut, O.
498 Laguda-Akingba, S. Gaseitsiwe, A. von Gottberg, T. de Oliveira, Emergence
499 of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med* **28**,
500 1785-1790 (2022).
- 501 2. N. P. Hachmann, J. Miller, A. Y. Collier, J. D. Ventura, J. Yu, M. Rowe, E. A.
502 Bondzie, O. Powers, N. Surve, K. Hall, D. H. Barouch, Neutralization Escape
503 by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J*
504 *Med* **387**, 86-88 (2022).
- 505 3. J. Quandt, A. Muik, N. Salisch, B. G. Lui, S. Lutz, K. Kruger, A. K. Wallisch, P.
506 Adams-Quack, M. Bacher, A. Finlayson, O. Ozhelvaci, I. Vogler, K. Grikscheit,
507 S. Hoehl, U. Goetsch, S. Ciesek, O. Tureci, U. Sahin, Omicron BA.1
508 breakthrough infection drives cross-variant neutralization and memory B cell
509 formation against conserved epitopes. *Sci Immunol* **7**, eabq2427 (2022).
- 510 4. C. I. Kaku, A. J. Bergeron, C. Ahlm, J. Normark, M. Sakharkar, M. N. E.
511 Forsell, L. M. Walker, Recall of preexisting cross-reactive B cell memory after
512 Omicron BA.1 breakthrough infection. *Sci Immunol* **7**, eabq3511 (2022).
- 513 5. M. Koutsakos, W. S. Lee, A. Reynaldi, H. X. Tan, G. Gare, P. Kinsella, K. C.
514 Liew, G. Tairaoa, D. A. Williamson, H. E. Kent, E. Stadler, D. Cromer, D. S.
515 Khoury, A. K. Wheatley, J. A. Juno, M. P. Davenport, S. J. Kent, The
516 magnitude and timing of recalled immunity after breakthrough infection is
517 shaped by SARS-CoV-2 variants. *Immunity* **55**, 1316-1326 e1314 (2022).
- 518 6. W. Wang, S. Lusvarghi, R. Subramanian, N. J. Epsi, R. Wang, E. Goguet, A.
519 C. Fries, F. Echegaray, R. Vassell, S. A. Coggins, S. A. Richard, D. A.
520 Lindholm, K. Mende, E. C. Ewers, D. T. Larson, R. E. Colombo, C. J.
521 Colombo, J. O. Joseph, J. S. Rozman, A. Smith, T. Lalani, C. M. Berjohn, R.
522 C. Maves, M. U. Jones, R. Mody, N. Huprikar, J. Livezey, D. Saunders, M.
523 Hollis-Perry, G. Wang, A. Ganesan, M. P. Simons, C. C. Broder, D. R. Tribble,
524 E. D. Laing, B. K. Agan, T. H. Burgess, E. Mitre, S. D. Pollett, L. C. Katzelnick,
525 C. D. Weiss, Antigenic cartography of well-characterized human sera shows
526 SARS-CoV-2 neutralization differences based on infection and vaccination
527 history. *Cell Host Microbe* **30**, 1745-1758 e1747 (2022).

- 528 7. O. Puhach, K. Adea, N. Hulo, P. Sattouet, C. Genecand, A. Iten, F.
529 Jacquerioz, L. Kaiser, P. Vetter, I. Eckerle, B. Meyer, Infectious viral load in
530 unvaccinated and vaccinated individuals infected with ancestral, Delta or
531 Omicron SARS-CoV-2. *Nat Med* **28**, 1491-1500 (2022).
- 532 8. T. C. Bouton, J. Atarere, J. Turcinovic, S. Seitz, C. Sher-Jan, M. Gilbert, L.
533 White, Z. Zhou, M. M. Hossain, V. Overbeck, L. Doucette-Stamm, J. Platt, H.
534 E. Landsberg, D. H. Hamer, C. Klapperich, K. R. Jacobson, J. H. Connor,
535 Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications
536 for timing of release from isolation: a longitudinal cohort study. *Clin Infect Dis*,
537 (2022).
- 538 9. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A.
539 Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing
540 antibody levels are highly predictive of immune protection from symptomatic
541 SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 542 10. Y. Cao, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, X.
543 Chen, N. Zhang, Y. Wang, P. Wang, L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu,
544 T. Xiao, Q. Gu, F. Shao, X. Hao, Y. Xu, R. Jin, Z. Shen, Y. Wang, X. S. Xie,
545 Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD
546 evolution. *bioRxiv*, 2022.2009.2015.507787 (2022).
- 547 11. C. I. Kaku, T. N. Starr, P. Zhou, H. L. Dugan, P. Khalife, G. Song, E. R.
548 Champney, D. W. Mielcarz, J. C. Geoghegan, D. R. Burton, R. Andrabi, J. D.
549 Bloom, L. M. Walker, Evolution of antibody immunity following Omicron BA.1
550 breakthrough infection. *bioRxiv*, (2022).
- 551 12. W. B. Alsoussi, S. K. Malladi, J. Q. Zhou, Z. Liu, B. Ying, W. Kim, A. J.
552 Schmitz, T. Lei, S. C. Horvath, A. J. Sturtz, K. M. McIntire, B. Evavold, F. Han,
553 S. M. Scheaffer, I. F. Fox, L. Parra-Rodriguez, R. Nachbagauer, B. Nestorova,
554 S. Chalkias, C. W. Farnsworth, M. K. Klebert, I. Pusic, B. S. Strnad, W. D.
555 Middleton, S. A. Teefey, S. P. J. Whelan, M. S. Diamond, R. Paris, J. A.
556 O'Halloran, R. M. Presti, J. S. Turner, A. H. Ellebedy, SARS-CoV-2 Omicron
557 boosting induces de novo B cell response in humans. *bioRxiv*, (2022).
- 558 13. R. K. Suryawanshi, I. P. Chen, T. Ma, A. M. Syed, N. Brazer, P. Saldhi, C. R.
559 Simoneau, A. Ciling, M. M. Khalid, B. Sreekumar, P. Y. Chen, G. R. Kumar, M.
560 Montano, R. Gascon, C. L. Tsou, M. A. Garcia-Knight, A. Sotomayor-
561 Gonzalez, V. Servellita, A. Gliwa, J. Nguyen, I. Silva, B. Milbes, N. Kojima, V.
562 Hess, M. Shacreaw, L. Lopez, M. Brobeck, F. Turner, F. W. Soveg, A. F.
563 George, X. Fang, M. Maishan, M. Matthay, M. K. Morris, D. Wadford, C.
564 Hanson, W. C. Greene, R. Andino, L. Spraggon, N. R. Roan, C. Y. Chiu, J. A.
565 Doudna, M. Ott, Limited cross-variant immunity from SARS-CoV-2 Omicron
566 without vaccination. *Nature* **607**, 351-355 (2022).
- 567 14. S. P. Andeweg, B. de Gier, D. Eggink, C. van den Ende, N. van Maarseveen,
568 L. Ali, B. Vlaemyneck, R. Schepers, S. J. M. Hahne, C. Reusken, H. E. de

- 569 Melker, S. van den Hof, M. J. Knol, Protection of COVID-19 vaccination and
570 previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2
571 infections. *Nat Commun* **13**, 4738 (2022).
- 572 15. H. N. Altarawneh, H. Chemaitelly, H. H. Ayoub, P. Tang, M. R. Hasan, H. M.
573 Yassine, H. A. Al-Khatib, M. K. Smatti, P. Coyle, Z. Al-Kanaani, E. Al-Kuwari,
574 A. Jeremijenko, A. H. Kaleeckal, A. N. Latif, R. M. Shaik, H. F. Abdul-Rahim,
575 G. K. Nasrallah, M. G. Al-Kuwari, A. A. Butt, H. E. Al-Romaihi, M. H. Al-Thani,
576 A. Al-Khal, R. Bertollini, L. J. Abu-Raddad, Effects of Previous Infection and
577 Vaccination on Symptomatic Omicron Infections. *N Engl J Med* **387**, 21-34
578 (2022).
- 579 16. A. A. Powell, F. Kirsebom, J. Stowe, M. E. Ramsay, J. Lopez-Bernal, N.
580 Andrews, S. N. Ladhani, Protection against symptomatic infection with delta
581 (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants
582 after previous infection and vaccination in adolescents in England, August,
583 2021-March, 2022: a national, observational, test-negative, case-control study.
584 *Lancet Infect Dis*, (2022).
- 585 17. N. Bobrovitz, H. Ware, X. Ma, Z. Li, R. Hosseini, C. Cao, A. Selemo, M.
586 Whelan, Z. Premji, H. Issa, B. Cheng, L. J. A. Raddad, D. Buckeridge, M. Van
587 Kerkhove, V. Piechotta, M. Higdon, A. Wilder-Smith, I. Bergeri, D. Feikin, R. K.
588 Arora, M. Patel, L. Subissi, Protective effectiveness of prior SARS-CoV-2
589 infection and hybrid immunity against Omicron infection and severe disease: a
590 systematic review and meta-regression. *medRxiv*, 2022.2010.2002.22280610
591 (2022).
- 592 18. C. Graham, T. Lechmere, A. Rehman, J. Seow, A. Kurshan, I. Huettnner, T. J.
593 A. Maguire, J. C. H. Tam, D. Cox, C. Ward, M. Racz, A. Waters, C. Mant, M.
594 H. Malim, J. Fox, K. J. Doores, The effect of Omicron breakthrough infection
595 and extended BNT162b2 booster dosing on neutralization breadth against
596 SARS-CoV-2 variants of concern. *PLoS Pathog* **18**, e1010882 (2022).
- 597 19. F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E.
598 Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I.
599 Shimeliovich, M. Daga, K. H. Yao, F. Schmidt, K. G. Millard, M. Turroja, M.
600 Jankovic, T. Y. Oliveira, A. Gazumyan, M. Caskey, T. Hatzioannou, P. D.
601 Bieniasz, M. C. Nussenzweig, Increased memory B cell potency and breadth
602 after a SARS-CoV-2 mRNA boost. *Nature* **607**, 128-134 (2022).
- 603 20. R. R. Goel, M. M. Painter, K. A. Lundgreen, S. A. Apostolidis, A. E. Baxter, J.
604 R. Giles, D. Mathew, A. Pattekar, A. Reynaldi, D. S. Khoury, S. Gouma, P.
605 Hicks, S. Dysinger, A. Hicks, H. Sharma, S. Herring, S. Korte, W. Kc, D. A.
606 Oldridge, R. I. Erickson, M. E. Weirick, C. M. McAllister, M. Awofolaju, N.
607 Tanenbaum, J. Dougherty, S. Long, K. D'Andrea, J. T. Hamilton, M.
608 McLaughlin, J. C. Williams, S. Adamski, O. Kuthuru, E. M. Drapeau, M. P.
609 Davenport, S. E. Hensley, P. Bates, A. R. Greenplate, E. J. Wherry, Efficient

- 610 recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2
611 mRNA vaccine. *Cell* **185**, 1875-1887 e1878 (2022).
- 612 21. A. Muik, B. G. Lui, M. Bacher, A. K. Wallisch, A. Toker, A. Finlayson, K.
613 Kruger, O. Ozhelvaci, K. Grikscheit, S. Hoehl, S. Ciesek, O. Tureci, U. Sahin,
614 Omicron BA.2 breakthrough infection enhances cross-neutralization of
615 BA.2.12.1 and BA.4/BA.5. *Sci Immunol* **7**, eade2283 (2022).
- 616 22. Y. Cao, W. Song, L. Wang, P. Liu, C. Yue, F. Jian, Y. Yu, A. Yisimayi, P.
617 Wang, Y. Wang, Q. Zhu, J. Deng, W. Fu, L. Yu, N. Zhang, J. Wang, T. Xiao,
618 R. An, J. Wang, L. Liu, S. Yang, X. Niu, Q. Gu, F. Shao, X. Hao, B. Meng, R.
619 K. Gupta, R. Jin, Y. Wang, X. S. Xie, X. Wang, Characterization of the
620 enhanced infectivity and antibody evasion of Omicron BA.2.75. *Cell Host*
621 *Microbe* **30**, 1527-1539 e1525 (2022).
- 622 23. R. Uraki, M. Ito, Y. Furusawa, S. Yamayoshi, K. Iwatsuki-Horimoto, E. Adachi,
623 M. Saito, M. Koga, T. Tsutsumi, S. Yamamoto, A. Otani, M. Kiso, Y. Sakai-
624 Tagawa, H. Ueki, H. Yotsuyanagi, M. Imai, Y. Kawaoka, Humoral immune
625 evasion of the omicron subvariants BQ.1.1 and XBB. *Lancet Infect Dis*,
626 (2022).
- 627 24. M. Hoffmann, G. M. N. Behrens, P. Arora, A. Kempf, I. Nehlmeier, A.
628 Cossmann, L. Manthey, A. Dopfer-Jablonka, S. Pohlmann, Effect of hybrid
629 immunity and bivalent booster vaccination on omicron sublineage
630 neutralisation. *Lancet Infect Dis*, (2022).
- 631 25. V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. K. Chu, T.
632 Bleicker, S. Brunink, J. Schneider, M. L. Schmidt, D. G. Mulders, B. L.
633 Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J. L.
634 Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M. P.
635 Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by
636 real-time RT-PCR. *Euro Surveill* **25**, (2020).
- 637 26. J. F. Chan, C. C. Yip, K. K. To, T. H. Tang, S. C. Wong, K. H. Leung, A. Y.
638 Fung, A. C. Ng, Z. Zou, H. W. Tsoi, G. K. Choi, A. R. Tam, V. C. Cheng, K. H.
639 Chan, O. T. Tsang, K. Y. Yuen, Improved Molecular Diagnosis of COVID-19
640 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time
641 Reverse Transcription-PCR Assay Validated In Vitro and with Clinical
642 Specimens. *J Clin Microbiol* **58**, (2020).
- 643 27. C. L. Hsieh, J. A. Goldsmith, J. M. Schaub, A. M. DiVenere, H. C. Kuo, K.
644 Javanmardi, K. C. Le, D. Wrapp, A. G. Lee, Y. Liu, C. W. Chou, P. O. Byrne,
645 C. K. Hjorth, N. V. Johnson, J. Ludes-Meyers, A. W. Nguyen, J. Park, N.
646 Wang, D. Amengor, J. J. Lavinder, G. C. Ippolito, J. A. Maynard, I. J.
647 Finkelstein, J. S. McLellan, Structure-based design of prefusion-stabilized
648 SARS-CoV-2 spikes. *Science* **369**, 1501-1505 (2020).

- 649 28. F. Tea, A. Ospina Stella, A. Aggarwal, D. Ross Darley, D. Pilli, D. Vitale, V.
650 Merheb, F. X. Z. Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown,
651 W. D. Rawlinson, S. R. Isaacs, V. Mathivanan, M. Hoffmann, S. Pohlman, O.
652 Mazigi, D. Christ, D. E. Dwyer, R. J. Rockett, V. Sintchenko, V. C. Hoad, D. O.
653 Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher, G. V. Matthews, F. Brilot, S. G.
654 Turville, SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and
655 evasion by emerging viral variants. *PLoS Med* **18**, e1003656 (2021).
- 656 29. J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R.
657 Esterbauer, H. E. Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm,
658 M. H. Dietrich, N. E. Scott, W. H. Tham, D. I. Godfrey, K. Subbarao, M. P.
659 Davenport, S. J. Kent, A. K. Wheatley, Humoral and circulating follicular
660 helper T cell responses in recovered patients with COVID-19. *Nat Med* **26**,
661 1428-1434 (2020).
- 662 30. D. Cromer, M. Steain, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, S.
663 J. Kent, J. A. Triccas, D. S. Khoury, M. P. Davenport, Neutralising antibody
664 titres as predictors of protection against SARS-CoV-2 variants and the impact
665 of boosting: a meta-analysis. *Lancet Microbe* **3**, e52-e61 (2022).
666
- 667

668 ***Acknowledgements***

669 We thank the participants for the generous involvement and provision of samples.

670 We thank Grace Gare and Andrew Kelly (University of Melbourne) for excellent

671 technical assistance. We thank molecular staff at the Victorian Infectious Diseases

672 Reference Laboratory for performing RT-PCR. We thank Dr Julian Druce and Dr

673 Leon Caly at the Victorian Infectious Diseases Reference Laboratory for isolating

674 and distributing SARS-CoV-2 virus isolates. We acknowledge the Melbourne

675 Cytometry Platform for provision of flow cytometry services.

676

677 ***Author contributions***

678 Conceptualization: WSL, HXT, JAJ, SJK, AKW

679 Formal Analysis: WSL, HXT, AR, DC, MPD, DSK, AKW

680 Funding Acquisition: MPD, SJK, AKW

681 Investigation: WSL, HXT, RE, MK, JN, TA, HEK, GT, PK, KCL, TT, AKW

682 Methodology: WSL, HXT, AR, AA, SGT, DSK, AKW

683 Resources: GT, PK, KCL, TT, AA, SGT, DAW

684 Supervision: DC, MPD, SJK, JAJ, DSK, AKW

685 Writing – original draft: WSL, HXT, AKW

686 Writing – review & editing: WSL, HXT, RE, MK, GT, DAW, MPD, SJK, JAJ, DSK,

687 AKW

688

689 ***Funding***

690 Australian National Health and Medical Research Council grants 1149990, 1162760

691 and 2004398

692 Australian Medical Research Future Fund grants 2005544 and 2013870

693 The Victorian Government

694 Australian National Health and Medical Research Council Investigator or Fellowship

695 grants (HXT, MK, DAW, MPD, SJK, JAJ, AKW)

696 Melbourne Postdoctoral Fellowship (WSL)

697

698 ***Competing interests***

699 The authors declare no competing interests.


700

701 ***Data and materials availability***

702 All data are available in the main text or the supplementary materials.

703

704 Figures



705

706 **Figure 1. Viral load kinetics and seroconversion to N following Omicron BA.1**

707 **and BA.2 breakthrough infection. (A)** Schematic of longitudinal sample collection

708 following breakthrough infection of vaccinated individuals with Omicron BA.1 (n=10)


709 or BA.2 (n=16). Each line represents a single subject, and each point represents a

710 sample collection (blue, nasal swab; red, blood; purple, both nasal swab and blood).

711 **(B)** Kinetics of SARS-CoV-2 viral load in nasal swabs measured by qPCR of the

712 nucleocapsid (N) gene. **(C)** Kinetics of plasma IgG titres against SARS-CoV-2


713 nucleocapsid (N) following breakthrough infection with BA.1 (red) or BA.2 (blue).
714 Subjects with previous SARS-CoV-2 infection are depicted in closed circles. The
715 thick lines represent the mean estimate from the piecewise linear regression model
716 using the estimated parameters.
717



718

719 **Figure 2. Omicron BA.1 and BA.2 breakthrough infection rapidly recalls**
 720 **neutralising antibodies that are broad and durable. (A) Kinetics of plasma**
 721 **neutralisation activity following breakthrough infection against ancestral VIC01 or**

722 matched infecting Omicron BA.1 and BA.2 strains. Thick lines represent the mean
723 estimate from the piecewise linear regression model using the estimated parameters.
724 Plasma neutralisation activity was measured using a live virus neutralisation assay
725 against SARS-CoV-2 clinical isolates in HEK293T cells transduced with ACE2 and
726 TMPRSS2. **(B)** Neutralisation mediated by BA.1 and BA.2 breakthrough plasma
727 against ancestral VIC01, Omicron BA.1, BA.2 and BA.4 strains at a median of 34
728 days post-symptom onset. Data are presented as median \pm IQR. **(C)** Longitudinal
729 decay kinetics of plasma neutralisation activity following breakthrough infection
730 against ancestral VIC01 or matched infecting Omicron BA.1 or BA.2 strains up to 4-7
731 months post-symptom onset. The best fit decay slopes (thick lines) are depicted. **(D)**
732 IgG antibody endpoint titres against BA.1 spike for BA.1 breakthrough subjects (red)
733 and against BA.2 spike for BA.2 breakthrough subjects (blue) following pre-
734 incubation with BSA control (closed circles) or ancestral Wuhan-hu-1 spike (open
735 circles).
736



737

738 **Figure 3. Omicron BA.1 and BA.2 breakthrough infection primarily recalls**


739 **memory B cells that are cross-reactive against ancestral spike.**

740 **(A)** Representative flow cytometry plots of memory B cells (CD19+ IgD-) stained with
741 ancestral (Wuhan Hu-1) and BA.1 or BA.2 fluorescent spike probes, from two
742 individuals with BA.1 breakthrough infection and two with BA.2 breakthrough
743 infection at around day 10 and 30 post-symptom onset. **(B)** Frequencies of memory
744 B cells (CD19+ IgD-) from BA.1 breakthrough subjects (red) and BA.2 breakthrough
745 subjects (blue) that are cross-reactive with Wuhan Hu-1 and BA.1/BA.2 spike (top) or
746 memory B cells that only recognise BA.1/BA.2 spike (bottom) over time. **(C)**
747 Frequencies of activated memory B cells (CD21- CD27+) that are cross-reactive or
748 specific for BA.1/BA.2 spike from BA.1 breakthrough subjects (red) and BA.2
749 breakthrough subjects (blue). **(D)** Antibody isotype distribution of cross-reactive or
750 BA.1/BA.2 spike-mono-specific memory B cells.

751

752

753




754

755 **Figure 4. Modelling the protective efficacy against symptomatic SARS-CoV-2**
756 **re-infection following BA.1 and BA.2 breakthrough infection. (A, B)** The
757 predicted decay in efficacy against symptomatic re-infection after peak neutralisation
758 (about day 30 post-symptom onset) based on the peak neutralisation titres observed
759 against ancestral virus (grey), the homologous infecting Omicron variants (blue) and
760 Omicron BA.4 (purple; which individuals had not yet encountered) using the
761 aggregate decay rate estimated. **(C, D)** The predicted decay in efficacy after peak
762 neutralisation titres given a theoretical loss of neutralisation (i.e. 1, 3, 10, or 30-fold
763 loss of neutralisation) to a new variant compared to the homologous neutralisation
764 titres after breakthrough infection (i.e. blue lines in A, B). Lines are predicted
765 efficacies and shaded regions indicate 95% confidence intervals of predicted
766 efficacies.

767

768 **Supplementary material**



769

770 **Figure S1. Gating strategy for the detection and phenotyping of spike-specific**
 771 **B cells. Lymphocytes were identified by FSC-A vs SSC-A gating, followed by**
 772 **doublet exclusion (FSC-A vs FSC-H), and gating on live CD19+ B cells. Class-**
 773 **switched B cells were identified as IgD-. Binding to SARS-CoV-2 ancestral Wuhan**
 774 **Hu-1 or Omicron (BA.1 or BA.2) spike was assessed. Cross-reactive (Wuhan Hu-1+**
 775 **Omicron+) or mono-specific (Omicron+) B cells were assessed for surface IgM, IgG**
 776 **or IgA isotypes, and CD21 and CD27 co-expression.**

777 **Supplementary Table 1.** Breakthrough infection cohort demographics

Subject	Gender	Breakthrough infection strain	Vaccination/infection history	No. of prior vaccinations and/or infections	Last vaccine to symptom onset (days)	Acute longitudinal sampling (Fig 1B,1C, 2A)	MBC analysis (Fig 3)	Decay analysis (Fig 2C)
COR015	F	BA.1	3x BNT162b2	3	38	□□	□□	□□
COR032	F	BA.1	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	32	□□	□□	□□
CP110	M	BA.1	2x BNT162b2	2	84	□□	□□	□□
CP111	M	BA.1	2x BNT162b2	2	100	□□	□□	
CP112	F	BA.1	2x BNT162b2	2	90	□□		
COR198	F	BA.1	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	39	□□	□□	□□
CP069	F	BA.1	Infection (Wuhan), 2x BNT162b2	3	111	□□	□□	□□
COR005	M	BA.1	1x NVX-CoV2373, 2x BNT162b2	3	102	□□	□□	□□
COR012	F	BA.1*	3x BNT162b2	3	38			□□
COR036	F	BA.2	2x BNT162b2, 1x mRNA-1273	3	90	□□	□□	
COR274	F	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	155	□□	□□	□□
COR275	M	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	83	□□	□□	□□
COR291	M	BA.2	3x BNT162b2	3	124	□□	□□	
COR039	F	BA.2	2x BNT162b2, 1 x mRNA-1273	3	169	□□		□□
COR215	F	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	125	□□	□□	□□
COR216	M	BA.2	2x ChAdOx1 nCoV-19,	3	122	□□		

			1x mRNA-1273					
CP120	F	BA.2	3x BNT162b2	3	151	□□		
COR043	F	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	64	□□	□□	□□
CP116	M	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	85	□□	□□	
CP117	M	BA.2	3x BNT162b2	3	52	□□	□□	□□
COR281	F	BA.2	3x BNT162b2	3	118	□□	□□	
CP118	M	BA.2	2x ChAdOx1 nCoV-19, 1x mRNA-1273	3	100	□□	□□	
CP119	F	BA.2	2x BNT162b2, 1x mRNA-1273	3	86	□□	□□	
CP40	M	BA.2	Infection (Wuhan), 2x ChAdOx1 nCoV-19, 1x BNT162b2	4	49	□□	□□	
COR011	F	BA.2*	3x BNT162b2	3	125			□□
COR282	M	BA.2*	3x BNT162b2	3	157			□□

778
779
780
781

*Nasal swabs to determine infecting variant were unavailable, thus infecting strain was assigned by predominant circulating strain at the time of infection.

782 **Supplementary Table 2.** Piecewise linear regression parameters of N-binding IgG (with 95% CI) following BA.1 or BA.2
 783 breakthrough infection. Related to Fig 1B.
 784

N IgG	Estimated parameter (95% CI)		
	BA.1 vs BA.2		
	BA.1	BA.2	p-value (for the difference)
Activation time (days post onset)	7.4 (5.4 - 8.7)	6.7 (3.4 - 9.6)	0.63
Doubling time (days)	2.4 (1.9 - 3.7)	1.5 (0.9 - 4)	0.08
Fold change (from baseline)	9 (1.6 - 16.5)	14.5 (7.9 - 21)	0.24

785

786

787 **Supplementary Table 3.** Piecewise linear regression parameters of neutralising antibodies (with 95% CI) following BA.1 or BA.2
 788 breakthrough infection. Related to Fig 2A.
 789

Neutralization IC ₅₀	Estimated parameter (95% CI)								
	BA.1 breakthrough infection			BA.2 breakthrough infection			BA.1 vs BA.2		
	WT	BA.1	p-value (for the difference)	WT	BA.2	p-value (for the difference)	BA.1	BA.2	p-value (for the difference)
Activation time (days post onset)	2.3 (0.3 - 20.3)	3.1 (1.5 - 6.6)	0.82	2.3 (0.8 - 7.2)	3.6 (2.4 - 5.6)	0.55	3.1 (1.5 - 6.6)	3.6 (2.4 - 5.6)	0.78
Doubling time (days)	6.1 (3.3 - 11.3)	2.1 (1.5 - 3)	0.02	7.8 (5.4 - 11.2)	2.8 (2.3 - 3.5)	0.000013	2.1 (1.5 - 3)	2.8 (2.3 - 3.5)	0.26
Fold change (from baseline)	5.4 (2.2 - 8.7)	31 (13.7 - 48.3)	0.0078	15.6 (6.5 - 37.8)	34.7 (11.9 - 57.4)	0.0042	31 (13.7 - 48.3)	34.7 (11.9 - 57.4)	0.53

790

791 **Supplementary Table 4.** Decay rates of neutralising antibodies (with 95% CI) following BA.1 or BA.2 breakthrough infection.
 792 Related to Fig 2C.
 793

Neutralization IC ₅₀	Estimated parameter (95% CI)								
	BA.1 breakthrough infection			BA.2 breakthrough infection			BA.1 vs BA.2		
	WT	BA.1	p-value (for the difference)	WT	BA.2	p-value (for the difference)	BA.1	BA.2	p-value (for the difference)
Half-life (days)*	182.8 (110.7 - 523.8)	333.5 (136.9 - 10000)	0.98	1216 (252.6 - 10000)	1049.7 (210.5 - 10000)	0.43	333.5 (136.9 - 10000)	1049.7 (210.5 - 10000)	0.36

794 *half-life upper limit is set to 10000 days